Cheng Rebecca, Cook Kirsty, Dowman Sarah, Lawn Rebecca, Leary Jemma, Quinn Taryn, Schroder Kim, Smith Nicola, Tordoff June
Pharmacy, University of Otago, New Zealand.
Pharm World Sci. 2005 Jun;27(3):236-42. doi: 10.1007/s11096-004-3706-x.
To identify the types of information used by health professionals when assessing a new medicine, and to discover whether measures of clinical effectiveness and cost-effectiveness are understood and used.
A cross-sectional survey of 56 health professionals was undertaken in a tertiary hospital in New Zealand. Respondents were consultants, registrars, house-surgeons, pharmacists, and specialist nurses
Health professionals' opinions on clinical and cost information required for assessing a new medicine; their ability to calculate measures of risk; and their ability to define clinical effectiveness, cost-effectiveness and types of economic analysis.
Thirty-four percent of respondents considered journals and research to be the most accurate sources of information when assessing a new medicine. Efficacy, safety, contraindications and side-effects were the most important information sought. In total, 93% gave an acceptable definition of clinical effectiveness, and 38% of cost-effectiveness. The majority of each profession (except specialist nurses) could calculate relative risk reduction (RRR) and absolute risk reduction (ARR) but fewer could calculate numbers needed to treat (NNT). Eighty-four percent of respondents felt that cost affected their assessment of a new medicine. Less than a quarter of respondents could define each type of economic analysis. Consultants and pharmacists appeared to have the best knowledge of economic analysis.
Efficacy, safety, contraindications and side-effects were the most important information sought when assessing a new medicine. Health professionals' knowledge of clinical effectiveness was greater than their knowledge of cost-effectiveness. Consultants and pharmacists appeared to have the best knowledge of economic analysis.
确定卫生专业人员在评估一种新药时所使用的信息类型,并了解他们是否理解和使用临床有效性及成本效益的衡量指标。
在新西兰一家三级医院对56名卫生专业人员进行了横断面调查。受访者包括顾问医生、住院医生、实习医生、药剂师和专科护士。
卫生专业人员对评估新药所需临床和成本信息的看法;他们计算风险衡量指标的能力;以及他们定义临床有效性、成本效益和经济分析类型的能力。
34%的受访者认为期刊和研究是评估新药时最准确的信息来源。疗效、安全性、禁忌症和副作用是他们最想了解的信息。总体而言,93%的人对临床有效性给出了可接受的定义,对成本效益给出可接受定义的比例为38%。每个专业的大多数人(专科护士除外)都能计算相对危险度降低率(RRR)和绝对危险度降低率(ARR),但能计算治疗所需人数(NNT)的人较少。84%的受访者认为成本会影响他们对新药的评估。不到四分之一的受访者能定义每种经济分析类型。顾问医生和药剂师似乎对经济分析了解最多。
评估新药时,疗效、安全性、禁忌症和副作用是最想了解的重要信息。卫生专业人员对临床有效性的了解比对成本效益的了解更多。顾问医生和药剂师似乎对经济分析了解最多。